Management of Tirzepatide Injection‑Site Reactions

Incidence and Typical Course

Injection‑site reactions occur in approximately 25 %–50 % of patients treated with tirzepatide in the SURPASS clinical trial program, are usually mild‑to‑moderate, and most resolve spontaneously within a few days. [1][2]

Mild‑to‑moderate injection‑site reactions do not require discontinuation of tirzepatide; therapy should be continued with local symptomatic measures. [1][2]
Therapy should be stopped only for severe (grade 3) or life‑threatening (grade 4) hypersensitivity reactions, such as symptomatic bronchospasm, dyspnea, hypoxia, wheezing, or anaphylaxis. [3][4]

A four‑grade severity system guides actions:
- Grade 1 (mild) – localized erythema, pruritus, or mild pain without functional impairment → continue therapy with local care. 4
- Grade 2 (moderate) – urticaria, swelling, or moderate pain with minimal functional impact → continue therapy; consider oral antihistamine. 4
- Grade 3 (severe) – extensive urticaria, marked swelling, or severe pain limiting self‑care → hold the dose and evaluate for hypersensitivity. 4
- Grade 4 (life‑threatening) – anaphylaxis, angioedema, or bronchospasm → permanently discontinue tirzepatide. 4

Apply a cold compress to the injection site immediately after injection to lessen pain, swelling, and erythema. 3
Avoid rubbing or massaging the injection site, as this may exacerbate local inflammation. 3
Use over‑the‑counter topical antihistamine or hydrocortisone cream for pruritus or persistent erythema. 3

Rotate injection sites systematically among abdomen, thigh, and upper arm to prevent repeated trauma. [1][2]
Do not inject into areas with visible bruising, redness, or induration from prior injections. [1][2]

Oral antihistamine pre‑medication (e.g., cetirizine 10 mg or diphenhydramine 25–50 mg) taken 30–60 minutes before injection may be considered for patients with recurrent, bothersome reactions, though it is not routinely required. [3][4]
Systemic corticosteroid pre‑medication is not indicated for isolated injection‑site reactions lacking systemic features. [3][4]

Distinguish localized injection‑site reactions from systemic hypersensitivity by looking for urticaria beyond the injection site, angioedema, dyspnea, wheezing, hypotension, or gastrointestinal symptoms occurring within minutes to hours after injection. [3][4]
If anaphylaxis is suspected, obtain a serum tryptase level within 1–2 hours of symptom onset. 4
Refer to allergy/immunology for patients with recurrent grade 2 reactions despite optimized technique or any grade 3 reaction. 4